You just read:

FDA Grants Breakthrough Therapy Designation for Avelumab in Combination with INLYTA® in Advanced Renal Cell Carcinoma

News provided by

Merck KGaA, Darmstadt, Germany

Dec 21, 2017, 12:00 EST